1
|
Teitelbaum DH, Guenter P, Griebel D, Abrams SA, Bark S, Baker M, Berry KL, Bistrian BR, Brenna JT, Bonnot D, Carpentier YA, Deckelbaum RJ, Hise M, Koletzko B, Mirtallo JM, Mulberg AE, O'Reilly RC, Shaffer J, von Kleist E, Zaloga GP, Ziegler TR. Proceedings From FDA/A.S.P.E.N. Public Workshop: Clinical Trial Design for Intravenous Fat Emulsion Products, October 29, 2013. JPEN J Parenter Enteral Nutr 2014; 39:768-86. [PMID: 25475623 DOI: 10.1177/0148607114560825] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Accepted: 10/23/2014] [Indexed: 01/08/2023]
Abstract
The development of intravenous fat emulsion (IVFE) is the culmination of physiological, biochemical, nutritional, and medical scientific advancements. IVFEs have the ability to deliver critical nutritional substrates to the patient. Recent literature purports that they may also play roles in modulation of immune functionality and pulmonary physiology, but data supporting these potential benefits are limited. While soybean-based IVFEs have comprised the dominant fat in U.S. markets, a number of other novel IVFEs may prove to optimize the care of children and adults in both hospitalized and home settings. The October 2013 U.S. Food and Drug Administration (FDA)/American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Public Workshop brought together scientists, researchers, and clinical experts to present updated clinical perspectives of IVFEs, including historical development, current state of usage throughout the world, and considerations for the regulatory approval of new IVFEs in the United States.
Collapse
Affiliation(s)
| | - Peggi Guenter
- American Society for Parenteral and Enteral Nutrition, Silver Spring, Maryland
| | - Donna Griebel
- Division of Gastroenterology and Inborn Error Products, Office of Drug Evaluation III, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
| | - Steven A Abrams
- Department of Pediatrics, Sections of Neonatology and USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas
| | - Staffan Bark
- Department of Surgery, Karolinska Institute, Stockholm, Sweden, and Department of Surgery, Visby Hospital, Visby, Sweden
| | | | - Karyn L Berry
- Division of Gastroenterology and Inborn Error Products, Office of Drug Evaluation III, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
| | - Bruce R Bistrian
- Harvard Medical School, Clinical Nutrition, Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | - J Thomas Brenna
- Division of Nutritional Sciences, Cornell University, Ithaca, New York
| | - Denis Bonnot
- Scientific Affairs, Business Unit, Parenteral Nutrition & Colloids, Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany
| | - Yvon A Carpentier
- Free University of Brussels (Université Libre de Bruxelles) and Lipid Nutrition Center, Brussels, Belgium
| | - Richard J Deckelbaum
- Department of Pediatrics and Epidemiology, Institute of Human Nutrition, Columbia University Medical Center, New York, New York
| | - Mary Hise
- Baxter Healthcare, Deerfield, Illinois
| | - Berthold Koletzko
- Dr von Hauner Children's Hospital, University of Munich Medical Centre, Germany
| | - Jay M Mirtallo
- The Ohio State University, College of Pharmacy, Ohio State University, Columbus, Ohio
| | - Andrew E Mulberg
- Division of Gastroenterology and Inborn Error Products, Office of Drug Evaluation III, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland
| | | | - Jonathan Shaffer
- Intestinal Failure Unit, Salford Royal Hospital, University of Manchester, United Kingdom
| | - Elke von Kleist
- Hospital Care Division, B. Braun Melsungen AG, Melsungen, Germany
| | | | - Thomas R Ziegler
- Division of Endocrinology, Metabolism and Lipids and Emory Center for Clinical and Molecular Nutrition, Emory University Hospital, Atlanta, Georgia
| |
Collapse
|
4
|
Klein CJ, Stanek GS, Wiles CE. Overfeeding macronutrients to critically ill adults: metabolic complications. JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION 1998; 98:795-806. [PMID: 9664922 DOI: 10.1016/s0002-8223(98)00179-5] [Citation(s) in RCA: 207] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Metabolic complications from overfeeding critically ill patients are serious and sometimes fatal. Nutrition care is best provided through repeated evaluation of patients' responses to feeding. Nutrition support may need to be modified over time to maintain metabolic stability and promote recovery. This article describes the etiology of 10 metabolic complications of overfeeding. Guidelines for recommending macronutrients are discussed, as are factors that could increase the risk of overfeeding. Patients who are very small, very large, or very old are particularly vulnerable to overfeeding. Overfeeding protein has led to azotemia, hypertonic dehydration, and metabolic acidosis. Excessive carbohydrate infusion has resulted in hyperglycemia, hypertriglyceridemia, and hepatic steatosis. High-fat infusions have caused hypertriglyceridemia and fat-overload syndrome. Hypercapnia and refeeding syndrome have also been caused by aggressive overfeeding. Dietitians can prevent or curtail the metabolic complications of overfeeding by identifying patients at risk, providing adequate assessment, coordinating interdisciplinary care plans, and delivering timely and appropriate monitoring and intervention. Dietitians need to document complications, interventions, and the outcomes of their clinical care to evaluate the appropriateness of existing nutrition guidelines.
Collapse
Affiliation(s)
- C J Klein
- R. Adams Cowley Shock Trauma Center, Baltimore, MD 21201-1595, USA
| | | | | |
Collapse
|